Permanent Brachytherapy of Localized Prostate Cancer: Preliminary Results
![]() |
Park, Hye-Li
(Department of Radiation Oncology, CHA Bundang Medical Center, CHA University)
Chang, Sei-Kyung (Department of Radiation Oncology, CHA Bundang Medical Center, CHA University) Kim, Ja-Young (Department of Radiation Oncology, CHA Bundang Medical Center, CHA University) Lee, Bo-Mi (Department of Radiation Oncology, CHA Bundang Medical Center, CHA University) Ko, Seong-Young (Department of Radiation Oncology, CHA Bundang Medical Center, CHA University) Kim, Sung-Joon (Department of Radiation Oncology, CHA Bundang Medical Center, CHA University) Shin, Hyun-Soo (Department of Radiation Oncology, CHA Bundang Medical Center, CHA University) |
1 | Pinkawa M, Fischedick K, Piroth MD, et al. Healthrelated quality of life after permanent interstitial brachytherapy for prostate cancer: correlation with postimplant CT scan parameters. Strahlenther Onkol 2006;182:660-665 DOI ScienceOn |
2 | Masucci GL, Donath D, Tetreault-Laflamme A, et al. Comparison between high and low source activity seeds for I-125 permanent seed prostate brachytherapy. Int J Radiat Oncol Biol Phys 2010;78:781-786 DOI ScienceOn |
3 | Lee N, Wuu CS, Brody R, et al. Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;48:1457-1460 DOI ScienceOn |
4 | Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006;(4):CD006019 |
5 | Bria E, Cuppone F, Giannarelli D, et al. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? Meta-analysis of randomized trials. Cancer 2009;115:3446-3456 DOI ScienceOn |
6 | Potters L, Torre T, Ashley R, Leibel S. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol 2000;18:1187-1192 DOI |
7 | Willins J, Wallner K. CT-based dosimetry for transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1997;39:347-353 |
8 | Kleinberg L, Wallner K, Roy J, et al. Treatment-related symptoms during the first year following transperineal 125I prostate implantation. Int J Radiat Oncol Biol Phys 1994;28:985-990 DOI ScienceOn |
9 | Snyder KM, Stock RG, Hong SM, Lo YC, Stone NN. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2001;50:335-341 DOI ScienceOn |
10 | Waterman FM, Dicker AP. Probability of late rectal morbidity in 125I prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003;55:342-353 DOI ScienceOn |
11 | Albert M, Song JS, Schultz D, et al. Defining the rectal dose constraint for permanent radioactive seed implantation of the prostate. Urol Oncol 2008;26:147-152 DOI ScienceOn |
12 | Han BH, Wallner KE. Dosimetric and radiographic correlates to prostate brachytherapy-related rectal complications. Int J Cancer 2001;96:372-378 DOI ScienceOn |
13 | Crook J, McLean M, Catton C, Yeung I, Tsihlias J, Pintilie M. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 2002;52:453-460 DOI ScienceOn |
14 | Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999;44:789-799 DOI ScienceOn |
15 | Merrick GS, Butler WM, Wallner KE, Lief JH, Galbreath RW. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology 2002;60:650-655 DOI ScienceOn |
16 | Merrick GS, Butler WM, Wallner KE, et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005;61:32-43 DOI ScienceOn |
17 | Expert Panel on Radiation Oncology-Prostate, Frank SJ, Arterbery VE, et al. American College of Radiology appropriateness criteria permanent source brachytherapy for prostate cancer. Brachytherapy 2011. 2011 Apr 16 [Epub]. DOI:10.1016/j.brachy.2011.01.014 |
18 | Nag S, Bice W, DeWyngaert K, Prestidge B, Stock R, Yu Y. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 2000;46:221-230 DOI ScienceOn |
19 | Salembier C, Lavagnini P, Nickers P, et al. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol 2007;83:3-10 DOI ScienceOn |
20 | Chauveinc L, Flam T, Solignac S, et al. Prostate cancer brachytherapy: is real-time ultrasound-based dosimetry predictive of subsequent CT-based dose distribution calculation? A study of 450 patients by the Institut Curie/Hospital Cochin (Paris) Group. Int J Radiat Oncol Biol Phys 2004;59:691-695 DOI ScienceOn |
21 | Phan J, Swanson DA, Levy LB, Kudchadker RJ, Bruno TL, Frank SJ. Late rectal complications after prostate brachytherapy for localized prostate cancer: incidence and management. Cancer 2009;115:1827-1839 DOI ScienceOn |
22 | Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 1996;14:449-453 |
23 | Potters L, Huang D, Calugaru E, Fearn P, Lee L, Kattan MW. Importance of implant dosimetry for patients undergoing prostate brachytherapy. Urology 2003;62:1073-1077 DOI ScienceOn |
24 | Blasko JC, Grimm PD, Sylsvester JE, Cavanagh W. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000;57:273-278 DOI ScienceOn |
25 | Hoffman KE, Chen MH, Moran BJ, et al. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer. Cancer 2010;116:2590-2595 DOI ScienceOn |
26 | Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002;52:444-452 DOI ScienceOn |
27 | Dosoretz AM, Chen MH, Salenius SA, et al. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy. Cancer 2010;116:837-842 DOI ScienceOn |
28 | D'Amico AV, Moran BJ, Braccioforte MH, et al. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol 2009;27:3923-3928 DOI ScienceOn |
29 | Kupelian PA, Elshaikh M, Reddy CA, Zippe C, Klein EA. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002;20:3376-3385 DOI ScienceOn |
30 | Smith RP, Jones HA, Beriwal S, Gokhale A, Benoit R. Predictors of Urinary Morbidity in Cs-131 Prostate Brachytherapy Implants. Int J Radiat Oncol Biol Phys 2010. 2010 Sep 30 [Epub]. DOI:10.1016/j.ijrobp.2010.06.01 |
31 | Ferrer M, Suarez JF, Guedea F, et al. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;72:421-432 DOI ScienceOn |
32 | Crook JM, Potters L, Stock RG, Zelefsky MJ. Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk. Brachytherapy 2005;4:186-194 DOI ScienceOn |
33 | Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-974 DOI ScienceOn |
34 | Kuban DA, Levy LB, Potters L, et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006;65:1487-1493 DOI ScienceOn |
35 | Taira AV, Merrick GS, Butler WM, et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2011;79:1336-1342 DOI ScienceOn |
36 | Marcus DM, Jani AB, Godette K, Rossi PJ. A review of low-dose-rate prostate brachytherapy: techniques and outcomes. J Natl Med Assoc 2010;102:500-510 DOI |
37 | Henderson A, Laing RW, Langley SE. Quality of life following treatment for early prostate cancer: does low dose rate (LDR) brachytherapy offer a better outcome? A review. Eur Urol 2004;45:134-141 DOI ScienceOn |
38 | Taira AV, Merrick GS, Galbreath RW, Wallner KE, Butler WM. Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2010;76:349-354 DOI ScienceOn |
![]() |